[go: up one dir, main page]

BR9813976A - Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto. - Google Patents

Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto.

Info

Publication number
BR9813976A
BR9813976A BR9813976-2A BR9813976A BR9813976A BR 9813976 A BR9813976 A BR 9813976A BR 9813976 A BR9813976 A BR 9813976A BR 9813976 A BR9813976 A BR 9813976A
Authority
BR
Brazil
Prior art keywords
compound
patient
processes
preparation
pharmaceutical composition
Prior art date
Application number
BR9813976-2A
Other languages
English (en)
Inventor
Richard Peter Charles Cousins
Brian Cox
Colin David Eldred
Andrew Michael Kenneth Pennell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9813976A publication Critical patent/BR9813976A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, PROCESSOS PARA O TRATAMENTO DE UM PACIENTE, E, PARA A PREPARAçãO DE UM COMPOSTO". Um composto de fórmula (I) que é um agonista de receptor de adenosina A1, em que R² representa alquila C~ 1-3~ , halogênio ou hidrogênio, R³ representa um grupo alquila reto ou ramificado, fluorado, de 1-6 átomos de carbono, e sais e solvatos dos mesmos, particularmente solvatos fisiologicamente aceitáveis, e sais dos mesmos. Estes compostos são agonistas no receptor de adenosina A1.
BR9813976-2A 1997-11-08 1998-11-06 Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto. BR9813976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9723589.9A GB9723589D0 (en) 1997-11-08 1997-11-08 Chemical compounds
PCT/EP1998/007021 WO1999024449A2 (en) 1997-11-08 1998-11-06 Adenosine a1 receptor agonists

Publications (1)

Publication Number Publication Date
BR9813976A true BR9813976A (pt) 2000-09-26

Family

ID=10821760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9813976-2A BR9813976A (pt) 1997-11-08 1998-11-06 Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto.

Country Status (29)

Country Link
US (1) US6455510B1 (pt)
EP (2) EP1457495A1 (pt)
JP (1) JP2001522857A (pt)
KR (1) KR20010031875A (pt)
CN (1) CN1285843A (pt)
AP (1) AP2000001801A0 (pt)
AR (1) AR011229A1 (pt)
AT (1) ATE273990T1 (pt)
AU (1) AU2048399A (pt)
BR (1) BR9813976A (pt)
CA (1) CA2309200A1 (pt)
CO (1) CO5021135A1 (pt)
DE (1) DE69825780T2 (pt)
EA (1) EA200000392A1 (pt)
EE (1) EE200000285A (pt)
ES (1) ES2222621T3 (pt)
GB (1) GB9723589D0 (pt)
HR (1) HRP20000275A2 (pt)
HU (1) HUP0004082A2 (pt)
IL (1) IL135964A0 (pt)
IS (1) IS5477A (pt)
MA (1) MA26565A1 (pt)
NO (1) NO20002361L (pt)
PE (1) PE20000013A1 (pt)
PL (1) PL340921A1 (pt)
SK (1) SK6722000A3 (pt)
TR (1) TR200002131T2 (pt)
WO (1) WO1999024449A2 (pt)
ZA (1) ZA9810125B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
NZ545787A (en) 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
EP1375508A1 (en) * 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
US7265111B2 (en) 2002-06-27 2007-09-04 Sanofi-Aventis Deutschland Gmbh Adenosine analogues and their use as pharmaceutical agents
FR2842810B1 (fr) * 2002-07-25 2006-01-27 Inst Nat Sciences Appliq Nouveaux composes gem difluores, leur procedes de preparation et leurs applications.
CN100480255C (zh) * 2002-08-15 2009-04-22 Cv医药有限公司 A1腺苷受体的部分和完全激动剂
NZ541651A (en) 2003-02-03 2009-01-31 Cv Therapeutics Inc Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005285284B2 (en) * 2004-09-09 2011-06-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Purine derivatives as A3 and A1 adenosine receptor agonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
WO2007120972A2 (en) * 2006-02-10 2007-10-25 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
US20100041662A1 (en) 2006-10-30 2010-02-18 Sandrine Ferrand Heterocyclic compounds as antiinflammatory agents
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201001135A1 (ru) * 2008-01-09 2011-02-28 ПиДжиИксХЭЛС ЭлЭлСи Интратекальное лечение невропатической боли агонистами ar
ES2442930T3 (es) 2008-01-11 2014-02-14 Novartis Ag Pirimidinas como inhibidores de cinasas
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
MX2017001461A (es) 2014-07-31 2017-05-11 Novartis Ag Terapia de combinacion.
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575959A (en) * 1969-05-13 1971-04-20 Merck & Co Inc 5'-substituted ribofuranosyl nucleosides
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1997033591A1 (en) * 1996-03-13 1997-09-18 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
GB9610031D0 (en) 1996-05-14 1996-07-17 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
IS5477A (is) 2000-05-03
HUP0004082A2 (hu) 2001-04-28
KR20010031875A (ko) 2001-04-16
HRP20000275A2 (en) 2000-12-31
EP1030857A2 (en) 2000-08-30
TR200002131T2 (tr) 2001-01-22
EA200000392A1 (ru) 2000-12-25
AP2000001801A0 (en) 2000-06-30
CN1285843A (zh) 2001-02-28
MA26565A1 (fr) 2004-12-20
NO20002361L (no) 2000-07-05
SK6722000A3 (en) 2001-01-18
CA2309200A1 (en) 1999-05-20
ES2222621T3 (es) 2005-02-01
AR011229A1 (es) 2000-08-02
EP1457495A1 (en) 2004-09-15
NO20002361D0 (no) 2000-05-05
JP2001522857A (ja) 2001-11-20
DE69825780T2 (de) 2005-01-13
PL340921A1 (en) 2001-03-12
WO1999024449A3 (en) 1999-08-19
ZA9810125B (en) 2000-05-05
PE20000013A1 (es) 2000-01-21
AU2048399A (en) 1999-05-31
CO5021135A1 (es) 2001-03-27
EE200000285A (et) 2001-08-15
ATE273990T1 (de) 2004-09-15
US6455510B1 (en) 2002-09-24
EP1030857B1 (en) 2004-08-18
IL135964A0 (en) 2001-05-20
WO1999024449A2 (en) 1999-05-20
DE69825780D1 (de) 2004-09-23
GB9723589D0 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
BR9813976A (pt) Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um paciente, e, para a preparação de um composto.
BR9813973A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição.
BR9813989A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo para o tratamento de um paciente sofrendo de uma condição
BR9911498A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para tratar de um paciente sofrendo de uma condição onde exista um benefìcio em reduzir a concentração de ácido graxo isento de plasma ou reduzir a frequência cardìaca
BR9914526A (pt) Derivados de adenina
NO933482L (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
ES545842A0 (es) Procedimiento para preparar difosfonatos
BR9813390A (pt) Composto, processo para a preparação do mesmo, e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, processo para efetuar a imunossupressão
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
AR012156A1 (es) BLOQUEADORES NEUROMUSCULARES DERIVADOS DE ISOQUINOLINIO DE ACCION ULTRA CORTA , COMPOSICION QUE LOS CONTIENE, USO DE DICHO COMPUESTO , INTERMEDIARIOS Y PROCESO PARA SU PREPARACIoN.
BR9808042A (pt) Composto, composição farmacêutica, e, processo para preparação de compostos.
DK602283A (da) Diethylaminoalkoxybenzhydrolderivater
DK0516350T3 (da) 2-hydroxy-2-phenylethylamin-derivater som beta-3-adrenoceptoragonister
AU586187B2 (en) 7-``2-(dialkylamino)ethyl``-4-hydroxy-1, 3-benzimidazol-2- ones
BR9808447A (pt) Composto, uso do mesmo, processo para sua preparação, e, composição farmacêutica
BR9809536A (pt) Mistura fungicida, processo para controlar fungos nocivos, uso dos compostos e, composição
SE8603589D0 (sv) Metylendioxifenantren- och stilbenderivat
BR9812234A (pt) Combinação de componentes, uso desta, processos para a preparação da mesma, para o tratamento de distúrbios afetivos, para o tratamento de depressão, e para melhorar o inìcio de ação terapêutica, formulação farmacêutica, e, kit
ES543799A0 (es) Procedimiento de preparacion de nuevos derivados 1-hidroxi- propilresorcinos provistos de un grupo fenilo sustituido
ES2054234T3 (es) Un procedimiento para la preparacion de derivados indol.
NO159380C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive amidazolderivater.
ES550817A0 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas
BR9713401A (pt) Moduladores de resistência a drogas e de resistência a múltiplas drogas.
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
DK118390A (da) Substituerede quinoliner

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]